Cubist isn’t the only life sciences acquisition in Boston today. Boston Heart Diagnostics, based in Framingham, MA, is getting bought by Eurofins for $140 million plus earn-outs of about $60 million based on achieving certain milestones. The deal is expected to be complete within 60 days.
Boston Heart Diagnostics is led by CEO Susan Hertzberg and has about 350 employees—all of whom will be retained, according to the company, which will continue as a wholly owned subsidiary of Eurofins. Eurofins Scientific is known for its bio-analytics testing and genomic services.
Boston Heart was founded in 2007 and has been backed by Bain Capital Ventures and other investors. The company makes diagnostic technologies for cardiovascular health management. It expects 2014 revenues of about $95 million.